Search

Displaying results 6161 - 6170 of 10000 in total
  1. Drug

    RUS 3108

    go.drugbank.com/drugs/DB05911
    Experimental

    The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers. … RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.

  2. Drug

    COVID19 s-vax loaded autologous dendritic cell vaccine

    go.drugbank.com/drugs/DB15814
    Experimental

    The rationale is that loading a DC cell with SARS-Cov-2 antigens and administering it as a vaccine can induce a more prolific immune response. … Dendritic cells (DCs) can be derived and differentiated from peripheral blood mononuclear cells in the presence of specific cytokines and growth factors.

  3. Drug

    SO-101

    go.drugbank.com/drugs/DB05345
    Experimental

    SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia.

  4. Drug

    BMS-564929

    go.drugbank.com/drugs/DB07286
    Experimental

    BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). … So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.

  5. Drug

    Atibuclimab

    go.drugbank.com/drugs/DB06546
    Investigational

    Atibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.

  6. Drug

    Influenza A virus A/California/7/2009 (H1N1)-like hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14382
    Approved

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  7. Drug

    Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14384
    ApprovedWithdrawn

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  8. Drug

    Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14386
    Approved

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  9. Drug

    Influenza B virus B/Texas/6/2011 hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14387
    Approved

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  10. Drug

    Influenza A virus A/Victoria/361/2011 (H3N2) live (attenuated) antigen

    go.drugbank.com/drugs/DB14395
    ApprovedWithdrawn

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen